Traditional Chinese medicine formula for treating atrophic gastritis with intestinal metaplasia and atypical hyperplasia and preparation method thereof

Abstract

The invention discloses a traditional Chinese medicine formula for treating atrophic gastritis with intestinal metaplasia and atypical hyperplasia and a preparation method thereof, and belongs to the technical field of traditional Chinese medicine formulas. The traditional Chinese medicine composition comprises the following components in parts by weight: 16-20 parts of Zhejiang radix ophiopogonis, 15-20 parts of moutan bark, 28-32 parts of salvia miltiorrhiza, 10-14 parts of pseudo-ginseng slices, 15-18 parts of curcuma zedoary, 18-22 parts of codonopsis pilosula, 28-32 parts of astragalus membranaceus and 28-32 parts of oldenlandia diffusa. The preparation method comprises the following steps: (1) cleaning the medicinal materials, and then cutting into small blocks to obtain a mixed medicinal material; (3) boiling with big fire after soaking, continuing to decoct with small fire, and filtering to obtain first medicine liquid and medicine residues; and (4) adding water again, boiling with big fire, continuously decocting with small fire, filtering to obtain a second liquid medicine, and mixing the first liquid medicine and the second liquid medicine. The traditional Chinese medicine composition can obviously improve inflammation and atrophic lesion of gastric mucosa, and has a remarkable effect on treating atrophic gastritis with intestinal metaplasia and atypical hyperplasia.

Description

TECHNICAL FIELD

[0001] The present application relates to the technical field of traditional Chinese medicine formula, more particularly, to a traditional Chinese medicine formula for treating atrophic gastritis with intestinal metaplasia and atypical hyperplasia. BACKGROUND

[0002] The most obvious feature of atrophic gastritis is that the gastric mucosa gradually thins, and the number of digestive glands in the stomach decreases, often causing symptoms such as stomach pain, bloating after eating, and indigestion. Atrophic gastritis with intestinal metaplasia is characterized by atrophy of the gastric mucosa and intestinal epithelial metaplasia. Atrophic gastritis with atypical hyperplasia refers to abnormal changes in gastric mucosa epithelial cells, deviating from the normal morphology and structure, and the changes are not typical.

[0003] Currently, the use of western medicine to treat atrophic gastritis with intestinal metaplasia and atypical hyperplasia has high side effects and the curative effect is not obvious. Western medicine mainly targets a single pathological link and is difficult to comprehensively intervene in the complex multi-factor pathological process of gastric mucosa atrophy and intestinal metaplasia. Moreover, it lacks means to regulate the overall gastric microenvironment, and cannot effectively block the multi-step carcinogenic process of "atrophy-intestinal metaplasia-atypical hyperplasia-gastric cancer". SUMMARY

[0004] The present application aims to overcome the shortcomings of the prior art and provide a traditional Chinese medicine formula for treating atrophic gastritis with intestinal metaplasia and atypical hyperplasia and a preparation method thereof, which can significantly improve inflammation and atrophic lesions of the gastric mucosa, promote the proliferation of tissue cells, enhance immune function, and reduce stress-induced gastric mucosal damage.

[0005] To achieve the above-mentioned purpose, the present application adopts the following technical solutions:

[0006] A traditional Chinese medicine formula for treating atrophic gastritis with intestinal metaplasia and atypical hyperplasia, with the following proportions by weight: Zhe Maidong 16-20 parts, Peony Bark 15-20 parts, Salvia Miltiorrhiza 28-32 parts, Sanchi 10-14 parts, Curcuma 15-18 parts, Codonopsis 18-22 parts, Astragalus 28-32 parts, and Oldenlandia 28-32 parts.

[0007] Further, Zhe Maidong 18 parts, Peony Bark 18 parts, Salvia Miltiorrhiza 30 parts, Sanchi 12 parts, Curcuma 18 parts, Codonopsis 20 parts, Astragalus 30 parts, and Oldenlandia 30 parts.

[0008] A preparation method of a traditional Chinese medicine formula for treating atrophic gastritis with intestinal metaplasia and atypical hyperplasia, comprising the following steps:

[0009] (1) Wash Zhe Maidong, Peony Bark, Salvia Miltiorrhiza, Sanchi, Curcuma, Codonopsis, Astragalus, and Oldenlandia, then cut them into small pieces to obtain mixed medicinal materials;

[0010] (2) Put the mixed medicinal materials into a decoction appliance and soak them in water;

[0011] (3) After soaking, boil with high fire, change to continue to decoct with small fire, filter, to obtain first medicinal liquid and medicinal residue;

[0012] (4) Add water again, continue to decoct medicinal residue with high fire until boiling, change to continue to decoct with small fire, filter, to obtain second medicinal liquid, mix first medicinal liquid and second medicinal liquid.

[0013] Further, the soaking time in step (2) is 0.5-1h, and the mass ratio of water to mixed medicinal materials is 1:1-2; in step (4), the mass ratio of water to medicinal residue is 1:1-1.5.

[0014] Further, the small fire decocting time in step (3) is 30-50min; the small fire decocting time in step (4) is 20-30min.

[0015] In summary, the present application has the following beneficial effects:

[0016] In the present application, Zhemaidong can inhibit contraction of gastrointestinal smooth muscle; peony bark can reduce stress-induced gastric mucosal damage. Danshen can reduce the occurrence of stress-induced gastric mucosal damage, promote tissue repair and regeneration; sanchi tablet can delay malignant progression of gastric mucosal tissue; zedoary can improve gastric blood circulation, so that the gastric mucosa can be reconstructed, and can also inhibit intestinal epithelial metaplasia and atypical hyperplasia, and prevent early carcinogenesis. Astragalus has the effects of enhancing immune function, resisting tumors, resisting oxidation, etc.; Codonopsis can improve the body's stress resistance, resist ulcers, resist tumors, etc. Oldenlandia can eliminate inflammatory edema, promote local microcirculation, remove inflammatory mediators and toxins from the gastric mucosa, and accelerate the repair of mucosal damage, so that mucosal erosion and bleeding disappear. The present application can significantly improve inflammation and atrophic lesions of the gastric mucosa, reduce stress-induced gastric mucosal damage, reduce the symptoms of atrophic gastritis with intestinal metaplasia and atypical hyperplasia, promote tissue cell proliferation, and enhance immune function. DETAILED DESCRIPTION

[0017] The technical solutions in the embodiments of the present application will be clearly and completely described below. Obviously, the described embodiments are only part of the embodiments of the present application, rather than all the embodiments. Based on the embodiments in the present application, all other embodiments obtained by those skilled in the art without creative labor fall within the scope of protection of the present application.

[0018] A traditional Chinese medicine formula for treating atrophic gastritis with intestinal metaplasia and atypical hyperplasia, with the following ratio by weight: Zhemaidong 16-20 parts, peony bark 15-20 parts, danshen 28-32 parts, sanchi tablet 10-14 parts, zedoary 15-18 parts, codonopsis 18-22 parts, astragalus 28-32 parts, and oldenlandia 28-32 parts.

[0019] A preparation method of a traditional Chinese medicine formula for treating atrophic gastritis with intestinal metaplasia and dysplasia comprises the following steps:

[0020] (1) Washing Zheimaxian, peony root, salvia miltiorrhiza, panax notoginseng, curcuma zedoaria, codonopsis pilosula, astragalus membranaceus, and oldenlandia diffusa, and then cutting into small pieces to obtain mixed medicinal materials;

[0021] (2) Placing the mixed medicinal materials into a decocting device, adding water (the mass ratio of water to medicinal materials is 1:1-2), and soaking for 0.5-1 h;

[0022] (3) Boiling after soaking with a large fire, and continuing to decoct for 30-50 min with a small fire, filtering, and obtaining a first medicinal liquid and medicinal residues;

[0023] (4) Adding water again (the mass ratio of water to medicinal residues is 1:1-1.5), continuing to decoct the medicinal residues with a large fire until boiling, continuing to decoct for 20-30 min with a small fire, filtering, obtaining a second medicinal liquid, and mixing the first medicinal liquid and the second medicinal liquid.

[0024] 1. Example

[0025] Example 1

[0026] Washing 18 parts of Zheimaxian, 18 parts of peony root, 30 parts of salvia miltiorrhiza, 12 parts of panax notoginseng, 18 parts of curcuma zedoaria, 20 parts of codonopsis pilosula, 30 parts of astragalus membranaceus, and 30 parts of oldenlandia diffusa, placing in a sand pot, adding water (the mass ratio of water to medicinal materials is 1:1.5), soaking for 40 min, decocting with a large fire until boiling, decocting with a small fire for 40 min, filtering the medicinal residues, obtaining a first medicinal liquid and medicinal residues, adding water again (the mass ratio of water to medicinal residues is 1:1), boiling, decocting with a small fire for 25 min, filtering, obtaining a second medicinal liquid, and mixing the first medicinal liquid and the second medicinal liquid.

[0027] 2. Comparative Example

[0028] Comparative Example 1

[0029] Washing 18 parts of curcuma zedoaria, placing in a sand pot, adding water (the mass ratio of water to medicinal materials is 1:1.5), soaking for 40 min, decocting with a large fire until boiling, decocting with a small fire for 40 min, filtering the medicinal residues, obtaining a first medicinal liquid and medicinal residues, adding water again (the mass ratio of water to medicinal residues is 1:1), boiling, decocting with a small fire for 25 min, filtering, obtaining a second medicinal liquid, and mixing the first medicinal liquid and the second medicinal liquid.

[0030] Comparative Example 2

[0031] The same as the operation steps of Comparative Example 1, except that 18 parts of curcuma zedoaria are replaced by 30 parts of oldenlandia diffusa.

[0032] Comparative Example 3

[0033] The same as the operation steps of Example 1, except that the equal amount of Radix Curculiginis is replaced by Radix Rubi.

[0034] Comparative Example 4

[0035] The same as the operation steps of Example 1, except that the equal amount of Curcuma zedoaria is replaced by Curcuma aromatica.

[0036] Comparative Example 5

[0037] Zhimaidong 18 parts, Danshen 30 parts, Sanqi tablet 12 parts, Dangshen 20 parts, Huangqi 30 parts, Mudanpi 18 parts, and Curcuma zedoaria 18 parts are prepared into the traditional Chinese medicine preparation according to the operation of Example 1.

[0038] Comparative Example 6

[0039] Zhimaidong 18 parts, Danshen 30 parts, Sanqi tablet 12 parts, Dangshen 20 parts, Huangqi 30 parts, Mudanpi 18 parts, and Radix Curculiginis 30 parts are prepared into the traditional Chinese medicine preparation according to the operation of Example 1.

[0040] Comparative Example 7

[0041] Zhimaidong 18 parts, Danshen 30 parts, Sanqi tablet 12 parts, Dangshen 20 parts, Huangqi 30 parts, Radix Curculiginis 30 parts, and Curcuma zedoaria 18 parts are prepared into the traditional Chinese medicine preparation according to the operation of Example 1.

[0042] Comparative Example 8

[0043] The same as the operation steps of Comparative Example 1, except that Zhimaidong 18 parts, Mudanpi 18 parts, Danshen 30 parts, Sanqi tablet 12 parts, Dangshen 20 parts, and Huangqi 30 parts are cleaned.

[0044] 3. Rat test Verification of treatment of atrophic gastritis with intestinal metaplasia and atypical hyperplasia

[0045] 3.1 Grouping and establishment of rat model

[0046] Test object: 100 female SD rats and 100 male SD rats with initial body weight of 190-200 g are taken.

[0047] Take 10 rats, half male and half female, as a blank control group. The remaining rats are used as a modeling group to construct a model for 3 months. The rats in the modeling group are given 2 mL of a 60% ethanol solution by gavage on an empty stomach (once every 5 days in the first month, once every 7 days in the second month; during this period, a deoxycholic acid sodium solution with a pH of 7.5 and 20 mmol / L is used to replace water for free drinking), and in the third month, a 30% ethanol solution and a 20 mmol / L deoxycholic acid sodium solution are used to replace water for free drinking alternately every three days. During the model construction period, the rats are fed adequately for 2 days (without any restrictions) and fasted for 1 day. Before the end of the model construction, 10 rats are randomly taken for examination to confirm whether the modeling is successful. After the modeling is successful, 100 mice from the modeling group are randomly divided into a model control group, an example 1 group, a comparative example 1 group, a comparative example 2 group, a comparative example 3 group, a comparative example 4 group, a comparative example 5 group, a comparative example 6 group, a comparative example 7 group, and a comparative example 8 group, with 10 mice in each group.

[0048] 3.2 Gavage

[0049] The example 1 group, the comparative example 1 group, and the comparative example 8 group are given the corresponding traditional Chinese medicine preparations of example 1 and comparative examples 1 to 8 by gavage at a dose of 5 g / kg once a day for a total of 25 weeks.

[0050] The model control group: gavage with the same volume of distilled water as the above traditional Chinese medicine preparations;

[0051] The blank control group: gavage with the same volume of distilled water as the above traditional Chinese medicine preparations.

[0052] In addition to the above operations, each group normally eats and drinks, and after 28 days of continuous administration, the rats in each group are fasted for 24 hours (without water restriction), and the stomachs of the rats in each group are taken for examination.

[0053] 3.3 Detection

[0054] 3.3.1 Gastric juice detection

[0055] 3.3.1.1 Detection of pepsin activity: Take the gastric juice of the rats in each group and detect it using an ELISA kit (purchased from Wuhan Saipei Biological Technology Co., Ltd., with a product number of SP12902; and operated strictly according to the instructions). The detection results are shown in Table 1.

[0056] Table 1

[0057] Group PP (pg / mL) Blank control group 691.34±14.97 Model control group 988.71±16.48 Example 1 group 720.42±20.89 Comparative example 1 group 963.14±13.97 Comparative example 2 group 975.23±14.46 Comparative example 3 group 818.65±15.96 Comparative example 4 group 823.87±17.24 Comparative example 5 group 865.26±16.97 Comparative example 6 group 870.19±15.91 Comparative example 7 group 874.64±15.96 Comparative example 8 group 898.74±17.13

[0058] As can be seen from Table 1, compared with the blank control group, the PP of the rats after modeling increases, and the PP of the example 1 group, the comparative example 1 group to the comparative example 8 group decreases compared with the model control group, among which the example 1 group decreases significantly compared with the other groups, indicating that the traditional Chinese medicine formula of the present application is superior to the formulas of the above other groups.

[0059] 3.3.2 Blood test

[0060] 3.3.2.1 Detection of serum gastrin content: The serum of each group of rats was taken, and an ELISA kit (purchased from Wuhan Saipei Biological Technology Co., Ltd., with a product number of SP13322; and strictly operated according to the instructions) was used for detection. The detection results are shown in Table 2.

[0061] Table 2

[0062] Group GAS (pg / mL) Blank control group 53.14±3.19 Model control group 79.69±3.44 Example 1 group 55.87±3.28 Comparative example 1 group 77.88±4.97 Comparative example 2 group 78.94±4.19 Comparative example 3 group 63.92±3.88 Comparative example 4 group 64.75±4.25 Comparative example 5 group 67.33±3.98 Comparative example 6 group 68.31±4.18 Comparative example 7 group 69.45±3.88 Comparative example 8 group 72.84±4.25

[0063] As shown in Table 2, compared with the blank control group, the GAS of the rats after modeling increased, and the GAS of the Example 1 group, the Comparative Example 1 group to the Comparative Example 8 group decreased compared with the model control group. Among them, the effect of the Example 1 group was obvious compared with other groups.

[0064] 3.3.2.2 Detection of serum lipid peroxide (LPO) content and superoxide dismutase (SOD) activity:

[0065] The TBA method was used to detect the content of lipid peroxide in serum (calculated by MDA content): a malondialdehyde (MDA) detection kit (purchased from Shanghai Yuanye Biological Technology Co., Ltd., with a product number of R21870; and strictly operated according to the instructions) was used.

[0066] The NBT method was used to detect the activity of superoxide dismutase in serum: a total superoxide dismutase (SOD) detection kit (purchased from Shanghai Yuanye Biological Technology Co., Ltd., with a product number of R22261; and strictly operated according to the instructions) was used.

[0067] The detection results are shown in Table 3.

[0068] Table 3

[0069] Group LPO (μmol / mL) SOD (NU / mL) Blank control group 9.18±1.02 126.02±6.87 Model control group 18.54±2.14 79.41±5.98 Example 1 group 9.25±1.11 125.74±4.98 Comparative example 1 group 17.12±2.98 85.46±4.21 Comparative example 2 group 17.84±2.53 85.58±4.26 Comparative example 3 group 10.95±1.98 114.01±4.35 Comparative example 4 group 11.14±2.74 113.69±4.35 Comparative example 5 group 12.92±2.14 106.92±5.01 Comparative example 6 group 13.14±2.46 109.76±4.74 Comparative example 7 group 13.59±2.32 108.59±4.29 Comparative example 8 group 15.15±2.26 96.35±4.56

[0070] As shown in Table 3, compared with the blank control group, the LPO value of the rats after modeling increased, and the SOD activity decreased, the LPO value of the Example 1 group, the Comparative Example 1 group to the Comparative Example 8 group decreased compared with the model control group, and the SOD activity increased. Among them, the LPO value of the Example 1 group decreased obviously compared with other groups, and the SOD activity of the Example 1 group increased obviously compared with other groups, which indicated that the traditional Chinese medicine formula of the application could improve the antioxidant capacity, effectively reduce the gastric mucosa lesion, and effectively treat atrophic gastritis with intestinal metaplasia and dysplasia.

[0071] 4. Clinical test

[0072] 18 patients with different degrees of atrophic gastritis with intestinal metaplasia and dysplasia were treated with the traditional Chinese medicine preparation according to the present application, twice a day, and the clinical data are shown in Table 4 below. Table 4 is a comparison before and after treatment of chronic atrophic gastritis with intestinal metaplasia and dysplasia, and the results show that the traditional Chinese medicine preparation according to the present application can effectively alleviate the symptoms of atrophic gastritis with intestinal metaplasia and dysplasia.

[0073] Table 4

[0074] No. Gender Age Date of record Symptom before treatment Examination date after treatment for a period of time Symptom after treatment 1 Male 43 2022 / 3 / 2 Chronic moderate atrophic gastritis of antrum with moderate extensive intestinal metaplasia 2022 / 6 / 24 Light-moderate chronic inflammation of antral mucosa with focal intestinal metaplasia 2 Male 56 2022 / 3 / 22 Moderate chronic atrophic gastritis of antrum with moderate intestinal metaplasia 2022 / 7 / 13 Chronic inflammation of antral lesser curvature mucosa with mild intestinal metaplasia, chronic inflammation of antral greater curvature mucosa 3 Male 51 2021 / 4 / 10 Moderate chronic atrophic gastritis of antrum with moderate intestinal metaplasia, moderate chronic atrophic gastritis of incisura angularis with moderate intestinal metaplasia, focal glandular mild heterotypic hyperplasia 2021 / 8 / 10 Mild chronic atrophic gastritis of antrum with moderate intestinal metaplasia, mild chronic atrophic gastritis of lesser curvature of corpus / greater curvature of incisura angularis with mild intestinal metaplasia 4 Male 54 2021 / 7 / 23 Chronic moderate atrophic gastritis of antral mucosa with moderate intestinal metaplasia 2022 / 1 / 17 Chronic mild superficial gastritis of antral mucosa with focal atrophy, mild intestinal metaplasia 5 Male 63 2021 / 7 / 30 Chronic gastritis of antral mucosa: light-moderate intestinal metaplasia 2022 / 1 / 24 Mild chronic superficial gastritis of antral mucosa with intestinal metaplasia 6 Male 52 2021 / 11 / 22 Chronic gastritis of antral mucosa with mild chronic inflammation and moderate intestinal metaplasia 2022 / 4 / 16 Chronic mild superficial gastritis of gastric mucosa 7 Male 72 2022 / 8 / 30 Chronic moderate inflammation of antral mucosa, moderate intestinal metaplasia, focal epitheliomatous hyperplasia, low-grade intraepithelial neoplasm 2023 / 2 / 15 Chronic mild superficial gastritis of antral mucosa 8 Female 54 2022 / 6 / 3 Severe chronic atrophic gastritis of antrum with severe intestinal metaplasia, moderate chronic atrophic gastritis of incisura angularis with moderate intestinal metaplasia 2022 / 10 / 24 Chronic mild superficial gastritis of antral lesser curvature mucosa with focal intestinal metaplasia, chronic mild gastritis of incisura angularis mucosa with mild intestinal metaplasia 9 Male 77 2022 / 2 / 22 Chronic gastritis of antral mucosa with severe intestinal metaplasia 2022 / 8 / 12 Chronic gastritis of antral mucosa with mild intestinal metaplasia 10 Male 53 2022 / 11 / 11 Chronic inflammation of antral superficial mucosa, severe intestinal metaplasia, chronic inflammation of superficial mucosa of upper body of corpus, severe intestinal metaplasia, mucosal muscular hyperplasia 2023 / 4 / 4 Chronic atrophic gastritis with erosion 11 Female 62 2022 / 4 / 4 Moderate chronic inflammation of antral mucosa with severe intestinal metaplasia, moderate chronic inflammation of antral mucosa with severe intestinal metaplasia, partial glandular hyperplasia 2022 / 9 / 28 Mild chronic inflammation of antral and posterior wall mucosa with intestinal metaplasia 12 Male 38 2023 / 3 / 26 Chronic moderate superficial gastritis of mucosa, moderate intestinal metaplasia, mild active stage 2023 / 5 / 12 Chronic moderate superficial gastritis of antrum with mild intestinal metaplasia 13 Male 69 2022 / 12 / 6 Mild chronic inflammation of antral mucosa with severe intestinal metaplasia 2023 / 5 / 9 Chronic mild atrophic gastritis of antral mucosa with mild intestinal metaplasia 14 Female 59 2023 / 5 / 11 Mild chronic inflammation of mucosa (greater curvature of antrum) with moderate intestinal metaplasia 2023 / 10 / 27 Mild chronic inflammation of mucosa (antrum) with intestinal metaplasia 15 Female 72 2023 / 4 / 27 Mild chronic inflammation of mucosa (antrum), moderate intestinal metaplasia, partial intestinal metaplastic epithelial hyperplasia 2023 / 10 / 9 Chronic inflammation of mucosa (antrum) with mild intestinal metaplasia 16 Male 49 2023 / 12 / 1 Chronic mild-moderate inflammation of mucosa (antrum), moderate intestinal metaplasia 2024 / 5 / 27 Chronic mild superficial gastritis of mucosa (antrum) with focal atrophy and intestinal metaplasia 17 Male 67 2024 / 1 / 24 Chronic moderate atrophic gastritis of mucosa (antrum) with moderate intestinal metaplasia; chronic moderate-severe atrophic gastritis of mucosa (incisura angularis) with moderate-severe intestinal metaplasia 2024 / 6 / 19 Chronic mild atrophic gastritis of mucosa (antrum) with mild intestinal metaplasia 18 Female 41 2023 / 2 / 23 Chronic moderate inflammation with moderate intestinal metaplasia of the mucosa (posterior wall of the angularis) 2023 / 8 / 17 Chronic mild superficial inflammation of the mucosa (antrum)

[0075] In addition, it has been tested that the composition of the present application also has a therapeutic effect on lung injury, and the experiment is as follows:

[0076] 5.1 Grouping and establishment of rat model

[0077] Test object: 90 male SD rats with an initial body weight of 190-200 g.

[0078] Take 10 rats, anesthetize the rats by intraperitoneal injection of 10% chloral hydrate at a dose of 0.4 g / kg, and use them as a blank control group; the rest of the rats are anesthetized by intraperitoneal injection of 10% chloral hydrate at a dose of 0.4 g / kg, then placed on a fixed frame in a supine position, with the chest fully exposed to the irradiation range, the parts outside the lung are shielded with a lead plate, and a linear accelerator (6MV-X ray) is used for full chest vertical single irradiation (single irradiation dose is 20Gy; absorption dose rate is 300cGy / min; source-skin distance is 1m; irradiation time is 2h), and they are divided into a model control group, a positive control group, an example 1 group, a comparative example 1 group, a comparative example 2 group, a comparative example 5 group, a comparative example 6 group, and a comparative example 8 group, each with 10 rats.

[0079] 5.2 Gavage

[0080] Example 1 group: gavage with the corresponding traditional Chinese medicine preparation of example 1 at a dose of 5g / kg, once a day;

[0081] Blank control group: gavage with the same volume of normal saline as the above traditional Chinese medicine preparation;

[0082] Model control group: gavage with the same volume of normal saline as the above traditional Chinese medicine preparation;

[0083] Positive control group: gavage with 1mg / kg dose of dexamethasone;

[0084] Comparative example 1 group, comparative example 2 group, comparative example 5 group, comparative example 6 group, and comparative example 8 group: gavage with the corresponding traditional Chinese medicine preparation of comparative example 1, comparative example 2, comparative example 5, comparative example 6, and comparative example 8 at a dose of 5g / kg, once a day;

[0085] In addition to the above operations, each group normally eats and drinks, and continuous administration for 8 weeks.

[0086] 5.3 Detection

[0087] After the last administration of rats, 19% chloral hydrate was injected intraperitoneally to anesthetize, 5 mL of rat blood was taken through the heart, and the blood was allowed to stand for 30 min, and then centrifuged at 4℃, 3000 r / min for 20 min, and the supernatant was taken, and the contents of MDA, tumor necrosis factor-α (TNF-α), transforming growth factor-β1 (TGF-β1) in the serum of rats and the activity of SOD were detected by ELISA kit (the ELISA kit was purchased from Wuhan Saipei Biological Technology Co., Ltd.; the ELISA kit for detecting MDA was with the item number SP30131; the ELISA kit for detecting TNF-α was with the item number SP12250; the ELISA kit for detecting TGF-β1 was with the item number SP12253; and the ELISA kit for detecting SOD was with the item number SP12914). The detection results are shown in Table 5.

[0088] Table 5

[0089] Group MDA (U / mg) SOD (U / mg) TNF-α (ng / L) TGF-β1 (ng / L) blank control group 0.93±0.05 97.98±2.59 43.01±2.24 48.01±2.68 model control group 2.01±0.09 45.78±1.54 174.96±10.12 634.12±13.19 positive control group 1.64±0.08 64.35±2.19 114.78±9.19 392.67±9.49 Example 1 group 1.13±0.04 89.45±2.35 68.45±4.37 196.78±11.09 Comparative Example 1 group 1.87±0.05 49.98±2.47 160.59±8.09 607.25±10.09 Comparative Example 2 group 1.91±0.04 49.36±2.14 162.21±7.89 609.36±10.28 Comparative Example 5 group 1.39±0.05 73.12±2.09 103.95±5.01 291.62±11.21 Comparative Example 6 group 1.42±0.04 72.65±2.16 105.89±5.91 294.35±10.69 Comparative Example 8 group 1.57±0.05 65.89±2.08 112.45±6.02 312.56±11.01

[0090] As shown in Table 5, the contents of MDA, TNF-α and TGF-β1 in the serum of the model control group of rats increased significantly, and the activity of SOD decreased significantly; compared with the model control group, the contents of MDA, TNF-α and TGF-β1 in the positive control group were lower, and the activity of SOD was higher; compared with the positive control group, the contents of MDA, TNF-α and TGF-β1 in the Example 1 group decreased, and the activity of SOD increased; compared with the model control group, the contents of MDA, TNF-α and TGF-β1 in the Comparative Example 1 group, the Comparative Example 2 group, the Comparative Example 5 group, the Comparative Example 6 group and the Comparative Example 8 group all decreased, and the activity of SOD all increased; the effect of the Example 1 group was more obvious than those of other groups, which indicated that the traditional Chinese medicine preparation of the application had a reducing effect on radiation-induced lung injury.

[0091] The above only describes the preferred embodiments of the present application, and the protection scope of the present application is not limited to the above-described embodiments only, and any technical solutions falling within the concept of the present application shall fall within the protection scope of the present application. It should be noted that, for ordinary skilled persons in the technical field, some improvements and refinements without departing from the principles of the present application shall also be considered as the protection scope of the present application.

Claims

1. A Chinese medicine formula for treating atrophic gastritis with intestinal metaplasia and dysplasia, characterized in that, The proportion by weight parts is as follows: Zhe Mai Dong 16-20 parts, Mu Dan Pi 15-20 parts, Dan Shen 28-32 parts, Sanqi tablet 10-14 parts, E Zhu 15-18 parts, Dangshen 18-22 parts, Huangqi 28-32 parts, Baihua Sheche 28-32 parts.

2. The Chinese medicine formula according to claim 1 for treating atrophic gastritis with intestinal metaplasia and dysplasia, characterized in that, Zhe Mai Dong 18 parts, Mu Dan Pi 18 parts, Dan Shen 30 parts, Sanqi tablet 12 parts, E Zhu 18 parts, Dangshen 20 parts, Huangqi 30 parts, Baihua Sheche 30 parts.

3. A method for preparing the traditional Chinese medicine formula for treating atrophic gastritis with intestinal metaplasia and dysplasia according to claim 1, characterized in that, The preparation of the traditional Chinese medicine formula includes the following steps: (1) washing Zhe Mai Dong, Mu Dan Pi, Dan Shen, Sanqi tablet, E Zhu, Dangshen, Huangqi, Baihua Sheche, and then cutting into small pieces to obtain mixed medicinal materials; (2) putting the mixed medicinal materials into a decocting appliance and adding water for soaking; (3) after soaking, boiling with a large fire, and then continuing to decoct with a small fire, filtering to obtain a first medicinal liquid and a residue; (4) adding water again, and continuing to decoct the residue with a large fire until boiling, and then continuing to decoct with a small fire, filtering to obtain a second medicinal liquid, and mixing the first medicinal liquid and the second medicinal liquid.

4. The preparation method of the traditional Chinese medicine formula for treating atrophic gastritis with intestinal metaplasia and dysplasia according to claim 3, characterized in that, In step (2), the soaking time is 0.5-1h, and the mass ratio of water to mixed medicinal materials is 1:1-2; in step (4), the mass ratio of water to residue is 1:1-1.

5.

5. The preparation method of the traditional Chinese medicine formula for treating atrophic gastritis with intestinal metaplasia and dysplasia according to claim 3, characterized in that, In step (3), the decocting time with a small fire is 30-50min; in step (4), the decocting time with a small fire is 20-30min. In step (3), the decocting time with a small fire is 30-50min; in step (4), the decocting time with a small fire is 20-30min.